where 94 HCV patients were followed-up by 12 weeks during the antiviral therapy. All patients underwent liver biopsy and through laboratory data, the values for noninvasive methods, APRI, FIB-4 and GPR, were calculated to assess the accuracy of the tests in relation to liver biopsy, also considering the viral genotypes. RESULTS: The concordance of APRI in relation to liver biopsy for advanced fibrosis was AUROC = 0.67 (CI 95% 0.55-0.79). The GPR method represent an AUROC = 0.59 (CI 95% 0.46-0.73) for advanced fibrosis, while FIB-4 represent an AUROC = 0.69 (CI 95% 0.58-0.80) for advanced fibrosis. No significant difference was found when compared the three tests used (p = 0.306). Moreover, when evaluated the tests in relation to the viral genotypes, we found only statistical difference for GPR (p = 0.006), with better accuracy for genotype 2-3. CONCLUSION: We found association between viral genotypes and advanced fibrosis in the relationship of GPR; however, the results showed no good accuracy for all index evaluated in our population.
Introduction: Adverse effects of peginterferon/ribavirin therapy and sociodemographic factors are known to modify hematological parameters. The present study was aimed to evaluate the impact of sociodemographic characteristics on laboratorial blood profile during treatment of Chronic Hepatitis C (CHC). Method: This is a Cohort of 136 patients with CHC in treatment with peginterferon/ribavirin. Sociodemographic and laboratorial profile were collected in the baseline, 4th and 12th weeks of treatment. Results: The mean age of patients was 53±11.7 years, 78 (57.4%) were men, 119 (87.5%) were Caucasian. Hemoglobin levels decreased along the treatment from baseline (14.3 ±1.7 g/dL) to 4th (12.0 ±1.8 g/dL) and 12th (11.5 ±1.6 g/dL; p=0.001). Leukocytes values also decreased from baseline to 4th and 12th weeks of treatment (6805.6 ±6574.3/mm3; 3827.6 ±1650.3/mm3 and 3541 ±2056/mm3, respectively; p=0.001), as well as platelets values (175168.06 ±60846.7mm3, 138612.06 ±59356.6/mm3, and 127279.1 ±56333.6/mm3, respectively; p=0.001). Men had greater values of hemoglobin along treatment (p=0.001), while older (p=0.012) and non-Caucasian patients (p=0.008) have lower values. Platelets levels were reduced in older (p=0.007) and men patients (p=0.001) along treatment. Conclusion: social factors as sex, age, and ethnicity, showed greater impact on hematological variables during CHC treatment, revealing an important point to be considered since may influence the management of treatment.
AIM: The presente study we aim to evaluate the relationship between the single nucleotide polymorphism (SNP) rs12979860 in the IL28B gene with the diagnosis of depression and its symptoms along the treament of HCV patients. MATERIAL AND METHODS: Is a convenience cohort where patients were follow-up by 12 weeks during the antiviral therapy. A sociodemographic questionnaire, psychiatric diagnostic interview and laboratorial data were applied at the baseline, 4 th week and 12 th week of treatment. A sample of buccal cells was collected from each patient in the baseline and IL28B rs12979860 (C/T) polymorphism was genotyped by real-time PCR. RESULTS: 90 patients were evaluated in relation to IL28B rs12979860 (C/T) polymorphism. The rs12979860 polymorphism were not significantly associated with the diagnoses of major depression (p = 0.186) in the baseline, but along the treatment the T allele present a risk factor for irritability OR 3.75 [CI (1.22-11.57); p = 0.021]. Past depression is associated with the diagnosis of current depression pré treatment (p = 0.018). CONCLUSION: Our results suggest that patients carrying T-allele of rs12979860 have worst symptoms of depression related to those with CC genotype. These results indicate that genotypes of IL28B rs12979860 polymorphism should be better studied to be considered for further treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.